Taysha Gene Therapies, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsTaysha Gene Therapies is a clinical-stage AAV gene therapy company whose lead candidate TSHA-102 for Rett syndrome has completed dosing in its pivotal and ASPIRE trials and is approaching a potential BLA submission.
What they do
Taysha develops adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program TSHA-102 targeting Rett syndrome. The company has completed dosing in the REVEAL pivotal trial (17 patients) and the safety-focused ASPIRE trial (4 patients), and is preparing for a potential Biologics License Application (BLA). It is headquartered in Dallas, Texas, and is not yet generating product revenue.
Revenue drivers
- TSHA-102 for Rett syndrome — Lead gene therapy candidate; no commercial revenue yet, with potential BLA submission informed by a 6-month interim analysis of the REVEAL pivotal trial.
- Other CNS gene therapy programs — Earlier-stage pipeline of AAV-based therapies for severe monogenic CNS diseases; none are disclosed as generating revenue.
Recent performance
Annual revenue was $9.8 million in 2025, up from $8.3 million in 2024. The company reported no revenue in the quarters ended March 31, 2026 and June 30, 2026, with Q4 2025 revenue of $5.5 million. Net loss was $109.0 million in 2025 versus $89.3 million in 2024, and operating cash use was $93.1 million in 2025 versus $81.2 million in 2024. At June 30, 2026, Taysha held $455.4 million in cash and equivalents, $83.2 million in total liabilities, and $49.3 million in long-term debt.
Strategy
Taysha's stated focus is executing BLA-enabling activities for TSHA-102, with topline data from the REVEAL pivotal 6-month interim analysis and FDA feedback on the BLA submission pathway expected in the first half of 2027. The company is advancing commercial readiness, including market access and payer research, and expanded its partnership with Catalent to establish a commercial manufacturing framework. It completed a $230 million follow-on offering, which it says extends cash runway into the second half of 2028 and through a potential BLA approval. Management continues to evaluate next-generation technologies across its CNS gene therapy platform.
Risks
- Clinical and regulatory risk — The BLA submission pathway depends on REVEAL interim data and FDA feedback expected in 1H 2027, and a negative outcome could delay or prevent approval of TSHA-102.
- No product revenue — Taysha had no revenue in the quarters ended March 31, 2026 and June 30, 2026, and its historical revenue has not come from commercial product sales.
- Cash burn and financing need — Operating cash use was $93.1 million in 2025 and $81.2 million in 2024, and the company may need additional capital if planned activities or timelines change.
- Manufacturing and launch execution — Commercial readiness relies on the expanded Catalent partnership and internal market access planning, and failure to scale or secure reimbursement could impair a future launch.
Outlook
Management expects to report topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027. The company states its cash runway extends into the second half of 2028 and through potential BLA approval of TSHA-102. It also expects to continue commercial readiness and manufacturing scale-up activities ahead of a potential launch, if approved.